Vivanco et al. have shown that the catalytic activity of AKT is dispensable for cancer cell survival in certain contexts (e.g. in breast cancer cells with concurrent activating PIK3CA mutations and HER2 gene amplification, or lung cancer cells with MET gene amplification). This evidence concerns the gene AKT1 and cancer.